CalciMedica, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- A. Rachel Leheny
- Full Time Employees
- 16
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 505 Coast Boulevard South La Jolla CA United States of America 92037
- IPO Date
- Jun 14, 2023
- CIK
- 0001534133
- Website
- calcimedica.com
- Similar Companies
- Business
- CalciMedica, Inc. (NASDAQ: CALC) is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for life-threatening acute inflammatory and immunologic diseases, including acute kidney injury (AKI) with respiratory failure and acute pancreatitis (AP); its lead product candidate, Auxora (zegocractin), an intravenous CRAC channel inhibitor, targets immune response modulation and tissue protection in critical care settings with no approved disease-modifying treatments. Founded in 2007 and headquartered in La Jolla, California, the company advances its proprietary CRAC platform for severe conditions like pancreatic necrosis, distal organ failure, acute respiratory distress syndrome, chronic kidney disease, and end-stage renal disease, primarily serving intensive care unit (ICU) patients in the United States. CalciMedica reports approximately 170,000 annual U.S. hospitalizations for severe AP costing over $3 billion and impacts over 800,000 stage 2 or 3 AKI patients yearly with concurrent respiratory failure and roughly 50% 90-day mortality. In recent developments, CalciMedica completed a merger with Graybug Vision in 2023 providing approximately $34 million in cash; secured a credit facility of up to $32.5 million from Avenue Capital Group extending cash runway into mid-2026; announced a private placement of up to $55 million with investors including Deerfield Management and Soleus Capital affiliates; and published preclinical data in JCI Insight supporting CRAC inhibitors like CM5480 for pulmonary applications as of November 2025.
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
CalciMedica Pauses Kidney Study, Eyes New Trial In Pancreatitis
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
Airbus Clinches Contract to Supply 30 A320neo Aircraft to CALC
CalciMedica (NASDAQ:CALC) Trading Down 2.1% – Time to Sell?
CalciMedica Reports Third Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Announces Publication in JCI Insight of Preclinical Data Supporting CRAC Channel Inhibitor as a Potential Therapy for Pulmonary Arterial Hypertension
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025
CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™
CalciMedica to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
CalciMedica to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
CalciMedica Announces Publication in the American Journal of Nephrology Discussing Design and Rationale of Phase 2 KOURAGE Trial of Auxora™ in AKI with Respiratory Failure
CalciMedica Announces Upcoming Symposium at the 43rd Vicenza Course AKI-CRRT-EBPT and Critical Care Nephrology Meeting
CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates
CalciMedica Announces Presentations at Upcoming Medical Meetings
CalciMedica Inc. (CALC) Moves to Buy: Rationale Behind the Upgrade